Tech Company Financing Transactions
Surface Pharmaceuticals Funding Round
On 5/16/2018, Surface Pharmaceuticals landed $20 million in Series A investment from Flying L Partners.
Transaction Overview
Company Name
Announced On
5/16/2018
Transaction Type
Venture Equity
Amount
$20,000,000
Round
Series A
Investors
Flying L Partners (William Link)
Proceeds Purpose
Surface Pharmaceuticals intends to use the proceeds of the Series A financing to advance its clinical development programs focused on ocular surface disease, including Dry Eye Disease treatments, by seeking FDA approval for three drug candidates for up to five indications, as well as for general corporate purposes.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Undisclosed
San Francisco, CA 94105
USA
San Francisco, CA 94105
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Surface Pharmaceuticals, Inc. is a biopharmaceutical company focused on development and commercialization of innovative therapeutics for ocular diseases and is seeking FDA approval for its drug candidates through the Section 505(b)(2) regulatory pathway under the federal Food Drug & Cosmetic Act.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Kamran Hosseini
Browse more venture capital transactions:
Prev: 5/16/2018: Metawave venture capital transaction
Next: 5/16/2018: Auvik Networks venture capital transaction
Share this article
Where The Data Comes From
We document every notable VC transaction. VC transactions reported here are derived from publicly available VC deal announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs